New Alzheimer's drug THN391 enters first patient trial

NCT ID NCT06814730

Ongoing Disease control Sponsor: Therini Bio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This study tests an experimental drug called THN391 in 15 people with early Alzheimer's disease who also have small vessel disease in the brain. Participants receive three monthly IV infusions of either THN391 or a placebo. The main goal is to check safety and how the drug behaves in the body, not yet whether it helps memory or thinking.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: THN391 (an experimental drug given by IV infusion)
What this could lead to: If this drug is safe and well-tolerated, it could pave the way for larger studies to see if THN391 can slow or treat Alzheimer's disease.
What could go wrong: This is a very early, small study (15 people) focused only on safety and drug levels—not on whether it works. Many drugs that look safe in Phase 1 fail later. There may be side effects or no benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE, EARLY ONSET are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease early-onset autosomal dominant Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE, EARLY ONSET

Contacts and locations

Locations

Amsterdam UMC

Amsterdam, New Hampshire, Netherlands
CTC-Netherlands

Groningen, Provincie Groningen, 9713 EZ, Netherlands
Scottish Brain Sciences

Edinburgh, EH12 9DQ, United Kingdom
University College London Hospitals

London, WC1N 3BG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.